All changes in SPARCC score in patients grouped according to treatment.
| No Treatment | Stable NSAID/DMARD | Start NSAID/DMARD | Stop NSAID/DMARD | |
|---|---|---|---|---|
| Campaign 1 – baseline to 3 mos | ||||
| No SPARCC score change | n = 13 | n = 56 | n = 7 | n = 5 |
| Increase in SPARCC score | n = 4, mean: 5.9 (SD 7.1), range: 0.5 to 15.5 | n = 20, mean: 3.7 (SD 4.6), range: 0.5 to 16.0 | n = 3, mean: 4.5 (SD 3.5), range: 2 to 8.5 | — |
| Decrease in SPARCC score | n = 9, mean: −2.8 (SD 3.4), range: −11.0 to −0.5 | n = 29, mean: −4.9 (SD 4.9), range: −16.5 to −0.5 | n = 5, mean: −4.7 (SD 6.7), range: −16.5 to −0.5 | — |
| Campaign 2 – baseline to 3 mos | ||||
| No SPARCC score change | n = 4 | n = 31 | n = 8 | n = 5 |
| Increase in SPARCC score | — | n = 5, mean: 0.6 (SD 0.2), range: 0.5 to 1.0 | n = 1, mean: 5 (—) | — |
| Decrease in SPARCC score | n = 2, mean: −5.0 (SD 6.4), range: −12.5 to −0.5 | n = 10, mean: −4.6 (SD 3.3), range: −10.5 to −0.5 | n = 2, mean: −6.5 (SD 8.5), range: −12.5 to −0.5 | — |
| Campaign 2 – baseline to 1 yr | ||||
| No SPARCC score change | n = 10 | n = 28 | n = 7 | n = 6 |
| Increase in SPARCC score | — | n = 3, mean: 3.0 (SD 1.3), range: 1.5 to 4.0 | n = 1, mean: 12 (—) | n = 3, mean: 3.3 (SD 4.5), range: 0.5 to 8.5 |
| Decrease in SPARCC score | n = 3, mean: −6.8 (SD 8.5), range: −16.5 to −0.5 | n = 8, mean: −5.8 (SD 5.1), range: −14.5 to −1.0 | n = 1, mean: −0.5 (—) | n = 4, mean: −7.6 (SD 8.4), range: −18.0 to −0.5 |
SPARCC: SpondyloArthritis Research Consortium of Canada; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drug.